These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38589769)

  • 1. Nusinersen in adults with type 3 spinal muscular atrophy: long-term outcomes on motor and respiratory function.
    Serrão C; Domingues S; de Campos CF; Moreira S; Conceição I; de Carvalho M; Oliveira Santos M
    Neurol Sci; 2024 Jun; 45(6):2887-2891. PubMed ID: 38589769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen effectiveness and safety in pediatric patients with 5q-spinal muscular atrophy: a multi-center disease registry in China.
    Yao X; Peng J; Luo R; Wang X; Lu X; Wu L; Jin R; Zhong J; Liang J; Hong S; Yang L; Zhang X; Mao S; Hu J; Tao Z; Sun D; Wang H; Zhang L; Xia Y; Chen K; Wang Y
    J Neurol; 2024 Aug; 271(8):5378-5391. PubMed ID: 38954034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.
    Pera MC; Coratti G; Bovis F; Pane M; Pasternak A; Montes J; Sansone VA; Dunaway Young S; Duong T; Messina S; Mizzoni I; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Morando S; De Sanctis R; Sframeli M; Antonaci L; Frongia AL; Rohwer A; Scoto M; De Vivo DC; Darras BT; Day J; Martens W; Patanella KA; Bertini E; Muntoni F; Finkel R; Mercuri E;
    Ann Clin Transl Neurol; 2021 Aug; 8(8):1622-1634. PubMed ID: 34165911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nusinersen Initiation After Onset of Weakness Does Not Prevent Progression of Hip Instability.
    Kuong EE; Ip HNH; So NLW; To MKT; Chow W; Wong JSH; Chan SHS
    J Pediatr Orthop; 2024 Aug; 44(7):e657-e661. PubMed ID: 38689487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy.
    Yeo CJJ; Simeone SD; Townsend EL; Zhang RZ; Swoboda KJ
    J Neuromuscul Dis; 2020; 7(3):257-268. PubMed ID: 32333595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
    Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
    Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
    Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
    J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.